Defining high, medium and low impact prognostic factors for developing multiple sclerosisMar Tintoré, Xavier Montalbán, Àlex Rovira et al.|Brain|2015Cited by 520
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational studyThaís Armangué, María Jiménez‐Legido, Gemma Olivé-Cirera et al.|The Lancet Neurology|2020Cited by 326
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalbán, Heinz Wiendl, Christine Lebrun‐Frénay et al.|The Lancet Neurology|2025Cited by 314
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisCarmen Tur, Xavier Montalbán, Pere Carbonell‐Mirabent et al.|JAMA Neurology|2022Cited by 278
Brainstem lesions in clinically isolated syndromesMar Tintoré, Xavier Montalbán, Àlex Rovira et al.|Neurology|2010Cited by 195